SYBRON DENTAL SPECIALTIES INC - 10-Q Quarterly Report

Back to GetFilings.com

================================================================================

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

----------

FORM 10-Q

(MARK ONE)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2002

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 1-16057

----------

SYBRON DENTAL SPECIALTIES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE 33-0920985
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

1717 WEST COLLINS AVENUE, ORANGE, CALIFORNIA 92867
(Address of principal executive offices) (Zip Code)

(714) 516-7400
(Registrant's Telephone Number, Including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

At February 5, 2003, there were 38,023,246 shares of the Registrant's Common
Stock, par value $.01 per share, outstanding.

================================================================================

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

See accompanying notes to unaudited consolidated financial statements.

1

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)

See accompanying notes to unaudited consolidated financial statements.

2

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED DECEMBER 31, 2002
(UNAUDITED)

See accompanying notes to unaudited consolidated financial statements.

3

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

See accompanying notes to unaudited consolidated financial statements.

4

SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(DOLLARS IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)

1. OVERVIEW AND BASIS OF PRESENTATION

Sybron Dental Specialties, Inc. ("SDS" or the "Company") was incorporated in
Delaware on July 17, 2000. The Company was created to effect the spin-off by
Apogent Technologies Inc. ("Apogent") of its dental business. As a part of the
spin-off, which occurred on December 11, 2000, Apogent transferred to SDS, along
with certain other assets, all of the capital stock of Sybron Dental Management,
Inc. ("SDM"), which owned, directly or indirectly, the stock or other equity
interest in the subsidiaries that held substantially all of the assets and
liabilities of Apogent's then dental business. Apogent then distributed to its
shareholders, by means of pro rata distribution, all of the Company's
outstanding common stock together with related preferred stock purchase rights
(the "spin-off"). As a result, SDS became an independent, publicly traded
company. The subsidiaries of SDS market their products under brand names such as
Kerr(R), Hawe(R), Herculite(TM), Prodigy(R), Tytin(R), Demetron(R), Ormco(R),
Straight-Wire(R), inspire!(R), AOA(TM), Damon(TM), Diamond(R), Metrex(R) and
Metricide(R), which are well recognized in the dental, orthodontics and
infection prevention industries.

Prior to October 1, 2002, SDS had three business segments: a) Professional
Dental, b) Orthodontics and c) Infection Prevention. Effective October 1, 2002,
the Company consolidated its Infection Prevention segment into its Professional
Dental segment to reduce costs and coordinate marketing efforts for its
infection prevention products. As a result, all financial information presented
in this quarterly report combines the historical information of the Infection
Prevention and Professional Dental business segments into one reporting segment.

The reported net sales of the Company's Professional Dental and Orthodontics
segments were impacted by the transfer made by the Company between those
segments, in the fiscal quarter ending December 31, 2002, of its stainless steel
endodontic product line. While the responsibility for the sales and marketing of
those products was handled during fiscal year 2002 by the Orthodontics
segment, the net sales were reported in the Professional Dental business
segment. In the first quarter of the Company's 2003 fiscal year it transferred
the reporting of those sales to the Orthodontics business segment. While the
transfer impacted the respective results of operations reported for the
Professional Dental and Orthodontics segments, there was no impact on the
Company's consolidated results of operations for the quarter.

The unaudited consolidated financial statements reflect the operations of
SDS and its wholly owned subsidiaries and affiliates. The term "Apogent" as used
herein refers to Apogent Technologies Inc. and its subsidiaries. The Company's
fiscal year ends on September 30. All significant intercompany balances and
transactions have been eliminated in consolidation. The quarter ended December
31, 2002 and 2001 refer to the first quarters of fiscal years 2003 and 2002,
respectively. We have reclassified certain prior year data to conform to the
2003 presentation.

In the opinion of management, all adjustments, which are necessary for a
fair presentation of the results for the interim periods presented, have been
included. Except as described in notes 3 and 7 below, all such adjustments were
of a normal recurring nature. The results for the period ended December 31, 2002
are not necessarily indicative of the results to be expected for the full year.
Because certain disclosures have been omitted from these statements, this
information should only be read in conjunction with the Company's Annual Report
on Form 10-K for the fiscal year ended September 30, 2002.

2. INVENTORIES

Inventories at December 31, 2002 and September 30, 2002 are presented
below.

5

3. RESTRUCTURING CHARGES

In September 2002, the Company recorded a restructuring charge of
approximately $3,666 ($2,353 after tax) consisting primarily of severance and
termination costs associated with the planned termination of the employment of
71 employees employed at certain of the Company's European facilities, as a
result of the consolidation of those European facilities into the Company's Hawe
Neos facility in Switzerland. Of the $3,666 in restructuring charges,
approximately $3,064 are cash charges related to severance and contractual
obligations, $300 is a cash charge for an additional potential tax liability
included in income taxes payable, while the balance of approximately $302 are
non-cash charges. The Company expects to complete the majority of the 2002
restructuring plan by the 2003 fiscal year end.

In September 2001, the Company recorded a restructuring charge of
approximately $2,400 ($1,500 after tax) consisting primarily of the severance
and termination costs associated with the termination of the employment of 63
employees that were employed at Ormco's San Diego, California manufacturing
facility, as a result of the closing of the facility. The Company completed the
closing of the facility as of June 30, 2002 and finalized all remaining costs.
Work previously performed at the facility was absorbed into the Glendora,
California facility. The proceeds (approximately $5,265) from the sale of the
facility (which was completed on January 31, 2003) offset the amount of the
restructuring charge. The Company used the proceeds from the sale to pay down
debt.

In June 1998, SDS recorded a restructuring charge of approximately $14,600
(approximately $10,700 after tax) for the rationalization of certain acquired
companies, combination of certain duplicate production facilities, movement of
certain customer service and marketing functions, and the exiting of several
product lines.

The 2002 restructuring charge activity since September 2002 and its components
are as follows:

The 2001 restructuring charge activity since September 2001 and its components
are as follows:

6

The 1998 restructuring charge activity since June 1998 and its components are as
follows:

(a) The 2002 restructuring charge consists primarily of the charges for
severance and termination costs associated with the 71 employees
primarily located at several facilities throughout Europe whose
employment the Company plans to terminate as a result of the 2002
European restructuring plan. As of December 31, 2002, the employment of
15 of those 71 employees has been terminated. The 2001 restructuring
charge represents severance and termination costs associated with the
63 employees located at the Ormco San Diego facility whose employment
Ormco terminated as a result of the 2001 restructuring plan. As of
December 31, 2002, all of the employment terminations were completed
under the 2001 restructuring plan. The closing of the facility was
completed by June 30, 2002. The proceeds (approximately $5,265) from
the sale of the Ormco San Diego facility (which closed on January 31,
2003) offset the costs of closing the facility. The 1998 restructuring
charge represents severance and termination costs related to the 154
employees whose employment was terminated as a result of the 1998
restructuring plan. An adjustment of approximately $1,200 was made in
fiscal 1999 to adjust the accrual primarily representing over accruals
for anticipated costs associated with outplacement services, accrued
fringe benefits, and severance associated with employees who were
previously notified of termination and subsequently filled other
company positions.

(b) Amount represents lease payments and shutdown costs on exited
facilities.

(c) Amount represents write-offs of inventory and fixed assets associated
with discontinued product lines.

(d) The 2002 charge represents $300 in additional potential tax liability
included in income taxes payable. The 1998 charge of $700 represents a
statutory tax relating to assets transferred from an exited sales
facility in Switzerland.

(e) Amount represents certain terminated contractual obligations.

4. SEGMENT INFORMATION

The Company's operating subsidiaries are engaged in the manufacture and sale
of dental, orthodontics and infection prevention products in the United States
and other countries. Effective October 1, 2002, the Company consolidated the
Infection Prevention segment into the Professional Dental segment and also
transferred the reporting of the sales of its endodontic product line from its
Professional Dental segment to its Orthodontics segment. The prior period
information on the business segments has been adjusted to reflect the
consolidation of the Infection Prevention and Professional Dental segments. The
prior period information was not adjusted to reflect the transfer of the
endodontic product line.

Information on these business segments is summarized as follows:

7

5. EARNINGS PER SHARE

Basic earnings per share are calculated by dividing net income available to
common stockholders by the weighted average number of common shares outstanding
during the period. Diluted earnings per share are calculated by using the
weighted average number of common shares outstanding adjusted to include the
potentially dilutive effect of outstanding stock options. The basic weighted
average number of shares outstanding was 37,989,646 and 37,894,531 for the
quarters ended December 31, 2002 and 2001, respectively. The number of
incremental diluted shares was 268,948 and 1,386,307 for the quarters ended
December 31, 2002 and 2001, respectively, which represent the dilutive effect of
options outstanding. The number of shares issuable upon the exercise of stock
options which were not included in the calculation because they were
anti-dilutive, was 3,908,151 at a weighted average exercise price of $15.69 per
share in the quarter ended December 31, 2002. There were no anti-dilutive shares
for the quarter ended December 31, 2001.

6. CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The Company's domestic subsidiaries are guarantors of the Company's 8 1/8%
senior subordinated notes due 2012, on an unsecured senior subordinated basis.
Except to the extent necessary to avoid a fraudulent conveyance, the note
guarantees are full and unconditional. The notes and the subsidiary guarantees
are unsecured and subordinated to all of the Company's and the Company's
guarantor subsidiaries' existing and future unsubordinated debt, including debt
under the credit facility entered into on June 6, 2002.

Below are the unaudited condensed consolidating balance sheets as of
December 31, 2002 and September 30, 2002, statements of operations for the three
months ended December 31, 2002 and 2001, and statements of cash flows for the
three months ended December 31, 2002 and 2001, of Sybron Dental Specialties,
Inc. and its subsidiaries, reflecting the subsidiary guarantors of the 8 1/8%
senior subordinated notes.

Intercompany balances include receivables/payables incurred in the normal
course of business in addition to investments and loans transacted by
subsidiaries of the Company with other subsidiaries or with the Company.

8

CONDENSED CONSOLIDATING BALANCE SHEETS

9

CONDENSED CONSOLIDATING BALANCE SHEETS

10

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS

11

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

12

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

7. RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 141, "Business
Combinations" and SFAS No. 142, "Goodwill and Other Intangible Assets." SFAS No.
141 requires that the purchase method of accounting be used for all business
combinations. SFAS No. 141 specifies criteria that intangible assets acquired in
a business combination must meet to be recognized and reported separately from
goodwill. SFAS No. 142 requires that goodwill and intangible assets with
indefinite useful lives no longer be amortized to earnings, but instead tested
for impairment at least annually in accordance with the provisions of SFAS No.
142. SFAS No. 142 also requires that intangible assets with estimable useful
lives be amortized over their respective estimated useful lives to their
estimated residual values, and reviewed for impairment in accordance with SFAS
No. 121 and subsequently, SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets," after its adoption.

The Company adopted the provisions of SFAS No. 141 as of July 1, 2001, and
SFAS No. 142 as of October 1, 2002. Upon adoption of SFAS No. 142, the Company
was required to evaluate its existing intangible assets and goodwill that were
acquired in purchase business combinations, and make any necessary
reclassifications in order to conform with the new classification criteria in
SFAS No. 141 for recognition separate from goodwill.

Intangible Assets

The Company was required to reassess the useful lives and residual values of
all intangible assets acquired, and make any necessary amortization period
adjustments by the end of the first interim period after adoption. If an
intangible asset was identified as

13

having an indefinite useful life, the Company was required to test the
intangible asset for impairment in accordance with the provisions of SFAS No.
142 within the first interim period. Impairment is measured as the excess of
carrying value over the fair value of an intangible asset with an indefinite
life. Any impairment loss is to be measured as of the date of adoption and
recognized as the cumulative effect of a change in accounting principle in the
first interim period. The Company did not record any impairment charge upon the
adoption of SFAS No. 142.

Goodwill

In connection with SFAS No. 142's transitional goodwill impairment
evaluation, SFAS No. 142 required the Company to perform an assessment of
whether there was an indication that goodwill was impaired as of the date of
adoption, October 1, 2002. To accomplish this, the Company identified its
reporting units and determined the carrying value of each reporting unit by
assigning the assets and liabilities, including the existing goodwill and
intangible assets, to those reporting units as of October 1, 2002. The Company
then determined the fair value of each reporting unit and compared it to the
carrying amount of the reporting unit. The Company has determined that no
goodwill impairment was indicated as of October 1, 2002.

The Company recorded goodwill amortization expense in the amount of $2,173
for the three months ended December 31, 2001. No goodwill amortization expense
was recorded for the three months ended December 31, 2002.

Tables

The following table reconciles previously reported net income as if the
provisions of SFAS No. 142 were in effect in fiscal 2002:

SFAS No. 141 and SFAS No. 142 also require that the Company disclose the
following information related to its intangible assets still subject to
amortization. The following table details the balances of the amortizable
intangible assets as of December 31, 2002:

Additionally, SFAS No. 142 requires that the Company disclose the estimated
intangible asset amortization for each of the five twelve month periods
subsequent to December 31, 2002. The following table represents the estimated
amortization (calculated as of December 31, 2002) for each of the five twelve
month periods ending as of the date indicated:

14

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

When we use the terms "SDS," "we," "us," "Company," or "our" in this report,
unless the context requires otherwise, we are referring to Sybron Dental
Specialties, Inc. and its subsidiaries and their respective predecessors that
comprised Apogent's dental business prior to the spin-off. Our fiscal year ends
on September 30 and, accordingly, all references to quarters refer to our fiscal
quarters. The quarters ended December 31, 2002 and 2001 refer to the first
quarters of fiscal 2003 and 2002, respectively.

GENERAL

We are a leading global manufacturer and marketer of a broad range of
consumable dental products and related small equipment, as well as a
manufacturer and distributor of products for use in infection prevention in both
the medical and dental markets. On October 1, 2002, we consolidated our
Infection Prevention segment into our Professional Dental business segment to
reduce costs and coordinate marketing efforts for our infection prevention
products. As a result of this consolidation, our subsidiaries now operate in two
business segments:

o Professional Dental. We develop and manufacture a comprehensive line
of branded dental consumable products and consumable infection
prevention products sold through independent distributors to the
dental industry worldwide as well as to medical markets; and

o Orthodontics. We develop, manufacture, and market an array of
consumable orthodontic products and endodontic products to
orthodontic and endodontic specialists worldwide.

Our primary subsidiaries in each of our business segments are as follows:

It is our goal to become a premier global supplier of high quality dental
products. Key elements of our strategy to achieve this goal are: a focus on
developing innovative products, a consistent effort to improve our efficiency, a
constant attempt to increase revenue opportunities within the existing
marketplace and expand the marketplace through product innovation, and the
pursuit of strategic acquisitions, while continuing to focus on debt reduction
strategies.

RESULTS OF OPERATIONS

OVERVIEW

Our net sales for the fiscal quarter ended December 31, 2002 increased by
22.9% from the corresponding fiscal 2002 period. Operating income for the first
quarter of fiscal 2003 increased by 10% from the corresponding fiscal 2002
period.

Our domestic sales for the quarter ended December 31, 2002 increased by
24.1% from the corresponding fiscal 2002 period. International sales increased
by 21.3% for the quarter from the corresponding fiscal 2002 period. Without the
effect of currency fluctuations, international sales growth would have been
14.1% for the quarter from the corresponding fiscal 2002 period.

We believe that our increase in revenue is a result, in part of the changes
we made throughout our organization in the second half of the last fiscal year,
the introduction of our new LED curing light and the increased average tenure of
our sales force in the United States for our Orthodontics segment. The amount of
the increase, when compared to the corresponding prior year period, is magnified
by the low revenue generated by our Professional Dental segment in the first
quarter of our 2002 fiscal year. We expect to see continued revenue growth this
year, but do not expect it to be at the same level as our first fiscal 2003
quarter. In fact, we do not believe the second quarter revenue for fiscal 2003
will increase significantly over the corresponding prior year period, as the
sales for

15

the Professional Dental segment were robust in that quarter and we do not expect
the sales of our new LED curing light in our subsequent fiscal 2003 quarters
will be at the level we achieved in the first quarter.

The reported net sales of our Professional Dental and Orthodontics segments
were impacted by the transfer we made between those segments, in the fiscal
quarter ending December 31, 2002, of our stainless steel endodontic product
line. While the responsibility for the sales and marketing of those products was
handled during fiscal year 2002 by the Orthodontics segment, the net sales were
reported in our Professional Dental business segment. In the first quarter of
our 2003 fiscal year we transferred the reporting of those sales to the
Orthodontics business segment. While the transfer impacted the respective
results of operations we reported for the Professional Dental and Orthodontics
segments for fiscal 2003, there was no impact on our consolidated results of
operations for the quarter. We did not adjust the prior period information
reported for our Professional Dental and Orthodontics segments to reflect the
transfer of the endodontic product line.

During our first fiscal 2003 quarter, we upgraded our Oracle financial and
enterprise resource planning software to a more recent version of the software,
Oracle 11i. We tested the upgrade and did not find any significant issues but we
cannot be certain that there will not be compatibility or other conversion
issues in the future after the software is fully implemented and used.

During the second quarter of our 2003 fiscal year, we anticipate closing
several of the European offices of our Professional Dental segment. This is a
significant undertaking, as we will transition the handling of orders and
shipping of product from several locations in Europe to our Hawe Neos facility
in Switzerland. The Hawe facility will be handling orders in numerous languages
and shipping product to numerous points throughout Europe. We do not presently
expect any disruptions in our ability to accept and ship orders, but we cannot
be certain until the closings and the integration by Hawe is complete.

QUARTER ENDED DECEMBER 31, 2002 COMPARED TO THE QUARTER ENDED DECEMBER 31,
2001

NET SALES

Overall Company. Net sales for the first quarter of fiscal 2003 increased by
$22.4 million or 22.9% from the corresponding fiscal 2002 quarter.

Professional Dental. Increased net sales in the Professional Dental segment
resulted primarily from: (a) increased net sales of existing products
(approximately $6.0 million), (b) net sales of new products (approximately $5.2
million), (c) net sales of products from an acquired company (approximately $3.8
million), (d) favorable foreign currency fluctuations (approximately $1.8
million) and (e) reduced rebate expense (approximately $0.2 million). The
increase in net sales was partially offset by the transfer of the endodontic
product sales to the Orhtodontics segment (approximately $3.7 million).

Orthodontics. Increased net sales in the Orthodontics segment resulted
primarily from: (a) increased net sales of existing products (approximately $5.3
million), (b) the transfer of the endodontic product sales from the Professional
Dental segment (approximately $2.5 million), (c) favorable foreign currency
fluctuations (approximately $1.2 million) and (d) net sales of new products
(approximately $0.6 million). The increase in net sales was partially offset by
increased rebate expense (approximately $0.5 million).

GROSS PROFIT

Overall Company. Gross profit for the quarter ended December 31, 2002
increased by $9.9 million or 18.1% from the corresponding fiscal 2002 quarter.

16

Professional Dental. Increased gross profit in the Professional Dental
segment resulted primarily from: (a) increased net sales of existing products
(approximately $3.7 million), (b) unit volume relating to new products
(approximately $2.9 million), (c) margins relating to net sales of products from
an acquired company (approximately $2.4 million), (d) favorable foreign currency
fluctuations (approximately $1.0 million) and (e) reduced rebate expense
(approximately $0.2 million). The increase in gross profit was partially offset
by: (a) the transfer of the endodontic product line from the Professional Dental
segment to the Orthodontics segment (approximately $2.4 million), (b) an
unfavorable product mix (approximately $1.0 million), (c) unfavorable
manufacturing variances (approximately $0.8 million), (d) inventory reserve
adjustments (approximately $0.3 million, of which approximately $0.2 million is
due to an increase in obsolescence and approximately $0.1 million is due to
physical inventory adjustments) and (e) increased royalty expense (approximately
$0.1 million).

Orthodontics. Increased gross profit in the Orthodontics segment resulted
primarily from: (a) increased net sales of existing products (approximately $2.5
million), (b) the transfer of the endodontic product line from the Professional
Dental segment to the Orthodontics segment (approximately $1.3 million), (c)
favorable foreign currency fluctuations (approximately $1.2 million) and (d)
unit volume relating to new products (approximately $0.4 million). The increase
in gross profit was partially offset by: (a) increased rebate expense
(approximately $0.7 million) and (b) increased royalty expense (approximately
$0.4 million).

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Overall Company. Selling, general and administrative expenses for the
quarter ended December 31, 2002 increased by $7.9 million or 22.6% from the
corresponding fiscal 2002 quarter. As of October 1, 2002, we adopted SFAS No.
142 "Goodwill and Other Intangible Assets" and have ceased the amortization of
goodwill and other intangible assets resulting in decreased amortization expense
from the corresponding prior year period of approximately $2.1 million.

Professional Dental. Increased selling, general and administrative expenses
in the Professional Dental segment resulted primarily from: (a) increased
general and administrative expenses (approximately $2.6 million), (b) increased
selling and marketing expenses (approximately $2.4 million), (c) expenses
related to an acquisition (approximately $1.8 million) and (d) an increase in
expenses relating to foreign currency fluctuations (approximately $0.5 million).
The increase in selling, general and administrative expenses was partially
offset by a decrease in amortization expense of goodwill and other intangible
assets (approximately $1.5 million).

Orthodontics. Increased selling, general and administrative expenses in the
Orthodontics segment resulted primarily from: (a) increased general and
administrative expenses (approximately $1.4 million), (b) increased selling and
marketing expenses (approximately $1.1 million) and (c) increased expenses
related to foreign currency fluctuations (approximately $0.3 million). The
increase in selling, general and administrative expenses was partially offset by
a decrease in amortization expense of goodwill and other intangible assets
(approximately $0.7 million).

OPERATING INCOME

As a result of the foregoing, operating income in the first quarter of
fiscal 2003 increased by 10.0% or $1.9 million from operating income in the
corresponding quarter of fiscal 2002.

17

INTEREST EXPENSE

Interest expense was $5.6 million in the first quarter of fiscal 2003, a
decrease of $1.5 million from the corresponding fiscal 2002 quarter. The
decrease resulted from reduced average debt balances in the first quarter of
fiscal 2003 and reduced average interest rates on our credit facility.

INCOME TAXES

Taxes on income in the first quarter of fiscal 2003 were approximately $5.9
million, an increase of $1.1 million from the corresponding fiscal 2002 quarter.
The increase was primarily due to higher taxable earnings, partially offset by a
decrease in the effective tax rate for the quarter from 39.0% in fiscal 2002 to
38.0% in fiscal 2003.

NET INCOME

As a result of the foregoing, we had net income of $9.6 million in the
quarter ended December 31, 2002, as compared to net income of $7.5 million in
the corresponding fiscal 2002 period.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization of goodwill (prior to October 1, 2002) and
other intangible assets is allocated among the cost of sales, selling, general
and administrative expenses and other expense in the first quarter of fiscal
2003. Depreciation and amortization of other intangible assets decreased $2.1
million in the first quarter of fiscal 2003 compared to the same period in the
prior year primarily due to our discontinuing the amortization of goodwill and
certain other intangible assets in accordance SFAS No. 142.

CRITICAL ACCOUNTING POLICIES

In the first quarter of fiscal 2003, as a result of our adoption of SFAS No.
142, we evaluated our existing intangible assets and goodwill for impairment. In
connection with our impairment test for SFAS No. 142 (as detailed in note 7 to
our unaudited consolidated financial statements above), fair market valuations
were performed for each of the reporting units. These valuations required
certain assumptions from management regarding future operating performance as
well as various industry trends. Fluctuations in these assumptions could have a
material impact on the values ascribed to the reporting units and could result
in an indication of impairment. These assumptions include, but are not limited
to, estimated future cash flows, estimated sales growth, and weighted average
cost of capital for each of the reporting units. In order to make informed
assumptions, management relied on certain public information and statistical and
industry information as well as internal forecasts to determine the various
assumptions. In the event that the industry, general economic and company trends
change, these assumptions will change and impact the calculated fair market
values.

NEW ACCOUNTING PRONOUNCEMENTS

In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated
with Exit or Disposal Activities." SFAS No. 146 requires companies to recognize
costs associated with exit or disposal activities when they are incurred rather
than at the date of a commitment to an exit or disposal plan. Examples of costs
covered by the standard include lease termination costs and certain employee
severance costs that are associated with a restructuring, discontinued
operations, plant closing, or other exit or disposal activities. SFAS No. 146 is
effective prospectively for exit or disposal activities initiated after December
31, 2002, with earlier adoption encouraged. As the provisions of SFAS No. 146
are required to be applied prospectively after the adoption date, we cannot
determine the potential effects that adoption of SFAS No. 146 will have on our
consolidated financial statements.

In November 2002, the FASB issued Interpretation No. 45, "Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others" (the "Interpretation"), which addresses
the disclosure to be made by a guarantor in its interim and annual financial
statements about its obligations under guarantees. These disclosure requirements
are included in note 6 to the unaudited consolidated financial statements. The
Interpretation also requires the recognition of a liability by a guarantor at
the inception of certain guarantees.

The Interpretation requires the guarantor to recognize a liability for the
non-contingent component of the guarantee, this is the obligation to stand ready
to perform in the event that specified triggering events or conditions occur.
The initial measurement of this liability is the fair value of the guarantee at
inception. The recognition of the liability is required even if it is not
probable that payments will be required under the guarantee or if the guarantee
was issued with a premium payment or as part of a transaction with multiple
elements.

18

We have adopted the disclosure requirements of the Interpretation and will
apply the recognition and measurement provisions for all guarantees entered into
or modified after December 31, 2002.

On December 31, 2002 the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure," which amends SFAS No.
123, "Accounting for Stock-Based Compensation." SFAS No. 148 amends the
disclosure requirements in SFAS No. 123 for stock-based compensation for annual
periods ending after December 15, 2002 and for interim periods beginning after
December 15, 2002, including those companies that continue to recognize
stock-based compensation under APB Opinion No. 25, "Accounting for Stock Issued
to Employees." In addition, SFAS No. 148 provides three alternative transition
methods for companies that choose to adopt the fair value measurement provisions
of SFAS No. 123. For a complete explanation on the valuation of our stock-based
compensation consistent with the method prescribed by SFAS No. 123, please refer
to the notes to the consolidated financial statements included in our annual
report for fiscal year ended September 30, 2002. We currently believe that there
will be no impact to us upon adopting SFAS No. 148 other than the disclosure
requirements.

LIQUIDITY AND CAPITAL RESOURCES

We intend to fund our capital expenditure requirements, working capital
requirements, acquisitions, principal and interest payments, obligations under
the Sale/Leaseback (defined below), restructuring expenditures, other
liabilities and periodic expansion of facilities, to the extent available, with
funds provided by operations and short-term borrowings under the Revolver
(defined below). While cash provided from operating activities may be impacted
by lower revenues due to the slowing economy and the continued risk of a
competitive market and changes in demand for our products, we believe that our
cash flow from operations, unused amounts available under our Credit Facility
(defined below), and access to capital markets will be sufficient to satisfy our
future working capital, capital investment, acquisition and other financing
requirements for the foreseeable future. However, there can be no assurance that
this will be the case. To the extent that funds are not available from these
sources, particularly with respect to our acquisition strategy, we would have to
raise additional capital in another manner or curtail our acquisition strategy.

It is currently our intent to reduce total debt and to continue to pursue
our acquisition strategy when those acquisitions appear to be in the best
interest of the stockholders, taking into account our level of debt and interest
expense. If acquisitions continue at our historical pace, of which there can be
no assurance, we may require financing beyond the capacity of our Credit
Facility (defined below). In addition, certain acquisitions previously completed
contain "earnout provisions" requiring further payments in the future if certain
financial results are achieved by the acquired companies.

The statements contained in the immediately preceding paragraph concerning
our intent to continue to pursue our acquisition strategy are forward-looking
statements. Our ability to continue our acquisition strategy is subject to a
number of uncertainties, including, but not limited to, our ability to raise
capital beyond the capacity of our credit facilities and the availability of
suitable acquisition candidates at reasonable prices.

Approximately $22.1 million of cash was generated from operating activities
in the first three months of fiscal 2003, as compared to approximately $8.2
million from the same period of the prior year. The approximate $13.9 million
increase in cash flows from operations was primarily due to: (a) a decrease in
the net change in inventories from the prior year period of approximately $11.2
million, (b) an increase in the net change in accrued payroll and employee
benefits from the prior year period of approximately $7.7 million, (c) an
increase in the net change in other assets and liabilities of approximately $6.5
million from the prior year period, (d) an increase in the net change in other
current liabilities from the prior year period of approximately $5.6 million,
(e) an increase in the net change in accounts payable from the prior year period
of approximately $4.1 million, (f) a decrease in the net change in prepaid
expenses and other current assets from the prior year period of approximately
$3.1 million, (g) an increase in the net change of income taxes payable from the
prior year period of approximately $2.9 million, (h) increased earnings from the
prior year period of approximately $2.1 million, (i) an increase in the net
change in the loss (gain) on sales of property, plant and equipment from the
prior year period of approximately $0.4 million, (j) an increase in inventory
provisions from the prior year period of approximately $0.3 million, (k) an
increase in the amortization of deferred financing fees of approximately $0.2
million from the prior year period and (l) an increase in the provision for
losses on doubtful receivables from prior year period of approximately $0.1
million. The increase in cash flows from operations were partially offset by the
following: (a) an increase in the net change in accounts receivable from the
prior year period of approximately $20.9 million, (b) a decrease in the net
change in deferred income taxes from the prior year period of approximately $3.7
million, (c) a decrease in the net change in accrued interest of approximately
$3.0 million, (d) a decrease in amortization expense of goodwill and other
intangible assets from the prior year period of approximately $2.1 million, (e)
a decrease in the net change in the restructuring reserve of approximately $0.5
million and (f) a decrease in the tax benefit from issuance of our common stock
under our employee stock option plan of approximately $0.1 million from the
prior period.

19

Approximately $1.1 million of cash was used in investing activities in the
first three months of fiscal year 2003, a decrease of approximately $2.1 million
from the same period of the prior year. The decrease was primarily due to: (a) a
decrease in capital expenditures of approximately $2.5 million from the prior
year period and (b) a decrease in net payments for intangibles from the prior
year period of approximately $0.1 million, partially offset by decreased
proceeds from the sales of property, plant and equipment from the prior year
period of approximately $0.5 million.

Approximately $10.3 million of cash was used in financing activities in the
first three months of fiscal 2003, an increase of approximately $6.0 million
from the prior year period. The increase was primarily due to: (a) a decrease in
the net loan proceeds of approximately $5.4 million from the prior year period,
(b) an increase in deferred financing fees from the prior year period of
approximately $0.5 million and (c) a decrease in cash received from the exercise
of stock options of approximately $0.1 million from the prior year period.

CREDIT FACILITIES AND SENIOR SUBORDINATED NOTES

On June 6, 2002, we terminated our then existing $450.0 million credit
facility and entered into a $350.0 million syndicated credit facility for which
Credit Suisse First Boston is the administrative agent. The credit facility (the
"Credit Facility"), provides for a five-year $120.0 million revolving credit
facility (the "Revolver"), a seven-year $200.0 million term loan (the "Term Loan
B") and a five-year $30.0 million revolving credit facility (the "Euro
Tranche"). Sybron Dental Management, Inc., Kerr Corporation, Ormco Corporation
and Pinnacle Products, Inc. (the "Domestic Borrowers") are joint and several
borrowers under the Revolver and the Term Loan B, and Hawe Neos Holdings S.A.
("Hawe Neos") is the borrower under the Euro Tranche. In addition to the Credit
Facility, we completed the sale of $150.0 million of 8 1/8% senior subordinated
notes due 2012 (the "Senior Subordinated Notes") in a private offering. We used
the proceeds of the Term Loan B, together with proceeds from the issuance of the
Senior Subordinated Notes, to repay all of the $332.9 million of borrowings
outstanding as of June 6, 2002 under our previous credit facility.

The Credit Facility is jointly and severally guaranteed by Sybron Dental
Specialties, Inc., the Domestic Borrowers and each of our present and future
direct and indirect wholly-owned domestic subsidiaries, and is secured by
substantially all assets of each such entity, including the capital stock of
each domestic subsidiary. In addition, the Credit Facility is secured by a
pledge of 65% of the capital stock of each of our first-tier material foreign
subsidiaries. The Euro Tranche is also guaranteed by certain foreign
subsidiaries and is secured by a pledge of 100% of the capital stock of certain
foreign subsidiaries and by some of the assets of our Swiss subsidiary, Hawe
Neos, certain direct subsidiaries of Hawe Neos and certain of our other indirect
foreign subsidiaries.

The Credit Facility may be prepaid at any time without penalty except for
LIBOR and Euro-LIBOR breakage costs. Under the Credit Facility, subject to
certain exceptions, we are required to apply all of the proceeds from any
issuance of debt, half of the proceeds from any issuance of equity, half of our
excess annual cash flow and, subject to permitted reinvestments, all amounts
received in connection with any sale of our assets and casualty insurance and
condemnation or eminent domain proceedings, in each case to repay the
outstanding amounts under the facility.

The Term B Loan amortizes 1% annually for the first six years, payable
quarterly, with the balance to be paid in the seventh year in equal quarterly
installments. The Term B Loan bears interest, at our option, at either (a) the
LIBOR rate, plus between 225 and 275 basis points, or (b) between 125 and 175
basis points plus the higher of (i) the rate from time to time publicly
announced by Credit Suisse First Boston as its prime rate, or (ii) the rate
which is 1/2 of 1% in excess of the federal funds rate, in each case as
determined on a quarterly basis according to the rating of the Credit Facility
by Standard and Poor's and Moody's. The per annum initial interest rate for the
first six months was LIBOR, plus 250 basis points. As of December 31, 2002 the
amount outstanding on the Term B Loan was $154.2 million. The average interest
rate at December 31, 2002 on the Term B Loan was 5.09% after giving effect to
the interest rate swap agreements we had in effect as of that date.

The Revolver bears interest, at our option, at a per annum rate equal to
either (a) the LIBOR rate, plus between 175 and 250 basis points, or (b) between
75 and 150 basis points plus the higher of (i) the rate from time to time
publicly announced by Credit Suisse First Boston as its prime rate, or (ii) the
rate which is 1/2 of 1% in excess of the federal funds rate, in each case as
determined on a quarterly basis according to a leveraged-based pricing grid with
leverage ratios from 1.75x to 3.0x. The per annum initial interest rate on the
Revolver for the first six months was LIBOR plus 225 basis points. The annual
commitment fee on the unused portion of the Revolver will vary between 0.375% to
0.5% based on the quarterly leverage ratio. As of December 31, 2002 the amount
outstanding on the Revolver was $13.5 million. The average interest rate at
December 31, 2002 on the Revolver was 5.05%. The Revolver also provides for the
issuance of standby letters of credit and commercial letters of credit as
required in the ordinary course of business. As of December 31, 2002, a total of
$2.8 million in letters of credit was issued. As of December 31, 2002 the amount
available under the Revolver was $103.7 million.

20

The Euro Tranche will bear interest, at our option, at Euro-LIBOR or at base
rates with margins identical to those of the Revolver. The annual commitment fee
on the unused portion of the Euro Tranche will vary between 0.375% to 0.5% based
on the quarterly leverage ratio. As of December 31, 2002, there was no
outstanding balance under the Euro Tranche and the amount available was $30.0
million.

The Credit Facility contains certain covenants, including, without
limitation, restrictions on: (i) debt and liens, (ii) the sale of assets, (iii)
mergers, acquisitions and other business combinations, (iv) transactions with
affiliates, (v) capital expenditures, (vi) restricted payments, including
repurchase or redemptions of the notes, (vii) the repurchase or redemption of
stock from stockholders and (viii) loans and investments, as well as
prohibitions on the payment of cash dividends. The Credit Facility also has
certain financial covenants, including, without limitation, maximum leverage
ratios, minimum fixed charge coverage ratios, minimum net worth and maximum
capital expenditures.

Effective December 10, 2002, the Credit Facility was amended to allow the
purchase by the Company of up to $25.0 million of its common stock.

Our ability to meet our debt service requirements and to comply with such
covenants is dependent upon our future performance, which is subject to
financial, economic, competitive and other factors affecting us, many of which
are beyond our control. We were in compliance with all such covenants at
December 31, 2002.

Prior to June 6, 2002, we had a credit facility that we entered into in
connection with the spin-off on December 11, 2000, which allowed for borrowings
up to $450.0 million from ABN AMRO Bank N.V. and certain other lenders. This
credit facility was composed of a $150.0 million five year tranche A term loan,
a $150.0 million seven year tranche B term loan, under which Kerr and Ormco were
borrowers, and a five year revolving credit facility up to $150.0 million, under
which Sybron Dental Management, Inc., was the borrower.

The tranche A term loan bore interest primarily at the adjusted interbank
offered rate for Eurodollar deposits plus 275 basis points. The tranche B term
loan bore interest primarily at the adjusted interbank offered rate for
Eurodollar deposits plus 375 basis points. Borrowings under the previous
revolving credit facility generally bore interest on the same terms as those
under the tranche A term loan, plus we paid a commitment fee on the average
unused portion of the revolving credit facility of 0.5%.

In connection with entering into our Credit Facility on June 6, 2002, we
issued $150.0 million of Senior Subordinated Notes bearing interest at 8 1/8%,
maturing on June 15, 2012. The Senior Subordinated Notes are our unsecured
obligations, subordinated in right of payment to all our existing and future
senior debt in accordance with the subordination provisions of the indenture.

Prior to January 1, 2003, Sybron Dental Management, Inc. ("SDM") was a
guarantor subsidiary of Sybron Dental Specialties, Inc. ("SDS") for our Senior
Subordinated Notes. Effective January 1, 2003, the management company, SDM,
merged into SDS; however, as both SDS and SDM are guarantors of our Senior
Subordinated Notes, there will be no impact on the status of the guarantors of
the Senior Subordinated Notes.

The Senior Subordinated Notes are generally not redeemable at our option
before June 15, 2005. Some limited redemption is allowed if we receive cash from
an equity offering. At any time and from time to time on or after June 15, 2007,
we may redeem the Senior Subordinated Notes, in whole or in part, at a
redemption price equal to the percentage of principal amount set forth below
plus accrued and unpaid interest to the redemption date.

As a result of the terms of our Credit Facility, we are sensitive to a rise
in interest rates. A rise in interest rates would result in increased interest
expense on our outstanding debt with variable interest rates. In order to reduce
our sensitivity to interest rate increases, from time to time we enter into
interest rate swap agreements. As of December 31, 2002, we had three interest
rate swap agreements outstanding aggregating a notional amount of approximately
$60.7 million. Under the terms of the swap agreements, we are required to pay
fixed rate amounts equal to the swap agreement rates listed below. In exchange
for the payment of the fixed rate

21

amounts, we receive floating rate amounts equal to the three-month LIBOR rate in
effect on the date of the swap agreements and the subsequent reset dates. For
the swap agreements, the rate resets on the quarterly anniversary of the swap
agreement dates until the swap agreement's expiration dates. The net interest
rate paid by us on the indicated notional amount is approximately equal to the
sum of the relevant swap agreement rate plus the applicable Eurodollar rate
margin. The swap agreement rates and durations as of December 31, 2002 are as
follows:

SALE/LEASEBACK

In 1988, we completed the sale and leaseback (the "Sale/Leaseback") of our
then principal domestic manufacturing and office facilities with an unaffiliated
third party. The transaction has been accounted for as a financing for financial
statement purposes, thus the facilities remain in property, plant and equipment.
The transaction was treated as a sale for income tax purposes. The financing
obligation is being amortized over the initial 25-year lease term.

The initial term of each lease is 25 years with five five-year renewal
options. On the fifth anniversary of the leases and every five years thereafter
(including renewal terms), the rent is increased by the percentage equal to 75%
of the percentage increase in the Consumer Price Index over the preceding five
years. The percentage increase to the rent in any five-year period is capped at
15%. Beginning January 1, 1999 annual payments increased to $1.5 million. The
next adjustment will occur January 1, 2004. As a result of the spin-off, the
Sale/Leaseback was amended to extend the leases an additional 5 years, increase
the basic rent by $0.15 million per year, and provides us the option to purchase
the leased premises at fair market value from June 1, 2008 to May 31, 2009. We
pay all costs of maintenance and repair, insurance, taxes and all other expenses
associated with the properties.

We have the option to purchase the facilities according to the terms of any
bona fide offer received by the lessor from a third party at any time during the
term of the leases. We may be obligated to repurchase the property upon the
event of a breach of certain covenants or occurrence of certain other events.

CONTRACTUAL OBLIGATIONS AND OTHER COMMERCIAL COMMITMENTS

The following table lists our contractual obligations and other commercial
commitments for the indicated periods (calculated as of December 31, 2002);

CAUTIONARY FACTORS

This report contains, and other disclosures that we make from time to time
may contain, forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe,"
"continue," "estimate," "expect," "goal," "objective," "outlook," "could,"
"intend," "may," "might," "plan," "potential," "predict," "should," or "will" or
the negative of these terms or other comparable terminology signify
forward-looking statements. You should read statements that contain these words
carefully because they discuss our future expectations; contain projections of
our future results of operations or our financial conditions; or state other
forward-looking information.

Forward-looking statements involve known and unknown risks, uncertainties,
and other factors that may cause actual results, performance or achievements to
be materially different from any future results, performance or achievements
expressed or implied by any forward-looking statements. Although we believe the
expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results. In addition to the assumptions and other
factors referenced specifically in connection with such statements, the
following factors could impact our business and financial prospects and affect
our future results of operations and financial condition:

22

OUR SUBSTANTIAL LEVEL OF INDEBTEDNESS COULD ADVERSELY AFFECT OUR FINANCIAL
CONDITION.

We presently have, and will continue to have, a substantial amount of
indebtedness which required significant interest payments. As of December 31,
2002, we had $331.0 million in total long-term borrowings (including current
portion), and $139.6 million in stockholders' equity. In addition, subject to
restrictions in the indenture for our Senior Subordinated Notes and our Credit
Facility, we may incur additional indebtedness.

Our substantial level of indebtedness could have important consequences,
which include the following:

o our ability to obtain additional financing for working capital, capital
expenditures, acquisitions, or general corporate purposes may be
impaired;

o we must use a substantial portion of our cash flow from operations to
pay interest and principal on our Senior Subordinated Notes and other
indebtedness, which will reduce the funds available to us for other
purposes such as potential acquisitions and capital expenditures;

o we are exposed to fluctuations in interest rates, to the extent our
borrowings bear variable rates of interest, including through interest
rate swap agreements;

o we have a higher level of indebtedness than some of our competitors,
which may put us at a competitive disadvantage and reduce our
flexibility in planning for, or responding to, changing conditions in
our industry, including increased competition; and

o we are more vulnerable to general economic downturns and adverse
developments in our business.

From time to time we have engaged in interest rate hedges to mitigate the
impact of interest rate fluctuations. If we are unable to, or elect not to
employ interest rate hedges, it could have a material adverse effect on our
profitability.

In addition, our credit facility contains numerous restrictive operating
and financial covenants, which could limit our operating flexibility. Our
ability to pay or refinance our indebtedness will depend upon our future
operating performance, which will be affected by general economic, financial,
competitive, legislative, regulatory, and other factors beyond our control.
Increases in interest rates would adversely affect our cash flows and therefore
our results of operations. In addition, the terms of any additional debt or
equity financing that we may incur could restrict our operational flexibility
and prevent us from pursuing business opportunities of value to our
stockholders.

WE ARE A HOLDING COMPANY AND ARE DEPENDENT UPON DIVIDENDS, INTEREST INCOME
AND LOANS FROM OUR SUBSIDIARIES TO MEET OUR DEBT SERVICE OBLIGATIONS.

We are a United States holding company and conduct substantially all of our
operations through our subsidiaries, some of which are located in other
countries. Our ability to meet our debt service obligations will therefore be
dependent on receipt of dividends, interest income and loans from our direct and
indirect subsidiaries. Our subsidiaries may be limited in the amounts they are
permitted to pay as dividends to us on their capital stock as a result of
statutory and other contractual restrictions. In particular, there are
significant tax and other legal restrictions on the ability of non-U.S.
subsidiaries to remit money to us. As a result, some or all of our subsidiaries
may not be able to pay dividends to us. If they do not, we may not be able to
make debt service payments on our debt instruments.

FUTURE EXCHANGE RATE FLUCTUATIONS OR INFLATION MAY ADVERSELY AFFECT OUR
RESULTS OF OPERATIONS.

We manufacture many of our products, including those in our professional
dental business segment, in our facilities in Mexico, Canada, Switzerland and
Italy. These products are supported by our sales offices in Europe, Japan,
Australia, South America and Mexico. In fiscal 2002, our foreign facilities'
selling, general and administrative expenses represented approximately 27.7% of
our consolidated selling, general and administrative expenses while our foreign
sales represented approximately 41.5% of our total net sales.

We measure our financial position and results of operations from
substantially all of our international operations, other than most U.S. export
sales, using local currency of the countries in which we conduct such operations
and then translate them into U.S. dollars.

23

The reported income of our foreign subsidiaries will be impacted by a weakening
or strengthening of the U.S. dollar in relation to a particular local currency.
Our U.S. export sales may also be affected by foreign currency fluctuations
relative to the value of the U.S. dollar as foreign customers may adjust their
level of purchases according to the weakness or strength of their respective
currencies versus the U.S. dollar. In addition, any future increases in the
inflation rate in any country where we have operations may negatively affect our
results of operations. To the extent these local currencies appreciate against
the U.S. dollar, our business, financial condition and results of operations
could be adversely affected.

We have engaged in currency hedges to mitigate the impact of foreign
currency fluctuations. If we are unable to, or elect not to continue to employ
currency hedges, it could have a material adverse effect on our net sales and
profitability. As we expand our international presence, these risks may
increase.

ACQUISITIONS HAVE BEEN AND CONTINUE TO BE AN IMPORTANT PART OF OUR GROWTH
STRATEGY; FAILURE TO CONSUMMATE STRATEGIC ACQUISITIONS COULD LIMIT OUR GROWTH
AND FAILURE TO SUCCESSFULLY INTEGRATE ACQUISITIONS COULD ADVERSELY IMPACT OUR
RESULTS.

Our business strategy includes continued growth through strategic
acquisitions, which depends upon the availability of suitable acquisition
candidates at reasonable prices and our ability to quickly resolve transitional
challenges. Failure to consummate appropriate acquisitions would adversely
impact our growth and failure to successfully integrate them would adversely
affect our results. These challenges include integration of product lines, sales
forces and manufacturing facilities and decisions regarding divestitures, cost
reductions, and realizing other synergies. Also, these challenges involve risks
of employee turnover, disruption in product cycles and the loss of sales
momentum. We cannot be certain that we will successfully manage them in the
future. Also, our Credit Facility and the indenture for the Senior Subordinated
Notes limit our ability to consummate acquisitions by imposing various
conditions which must be satisfied.

OUR PROFITABILITY MAY BE AFFECTED BY FACTORS OUTSIDE OUR CONTROL.

Our ability to increase sales, and to profitably distribute and sell our
products, is subject to a number of risks, including changes in our business
relationships with our principal distributors, competitive risks such as the
entrance of additional competitors into our markets, pricing and technological
competition, risks associated with the development and marketing of new products
in order to remain competitive and risks associated with changes in demand for
dental services which can be affected by economic conditions, health care
reform, government regulation, and more stringent limits on expenditures by
dental insurance providers or governmental programs.

We strive to increase our margins by controlling our costs and by improving
our manufacturing efficiencies. There can be no assurance, however, that our
efforts will continue to be successful. Margins can be affected by many factors,
including competition, product mix, and the effect of acquisitions.

IF WE ARE UNABLE TO SUCCESSFULLY MANAGE GROWTH AND RETAIN QUALIFIED
PERSONNEL, WE MAY NOT BE ABLE TO COMPETE EFFECTIVELY AND OUR REVENUES MAY DROP
SIGNIFICANTLY.

We intend to continue to expand our business over time into new geographic
regions and additional products and services, subject to the sufficiency of our
cash resources and our ability to comply with the covenants in our various debt
instruments. Our future performance will depend, in large part, upon our ability
to implement and manage our growth effectively. Our growth in the future will
continue to place a significant strain on our administrative, operational, and
financial resources. We anticipate that, if we are successful in expanding our
business, we will be required to recruit and hire a substantial number of new
managerial, finance, accounting, and support personnel. Failure to retain and
attract additional management personnel who can manage our growth effectively
would have a material adverse effect on our performance. To manage our growth
successfully, we will also have to continue to improve and upgrade operational,
financial and accounting systems, controls and infrastructure as well as expand,
train and manage our employees. Our failure to manage the future expansion of
our business could have a material adverse effect on our revenues and
profitability.

Our ability to hire and retain competent employees is also subject to a
number of risks, including unionization of our non-union employees and changes
in relationships with our unionized employees. In particular, many of our
non-management employees in Europe are subject to national labor contracts,
which are negotiated from time to time at the national level between the
national labor union and the employees' council. There is a risk of strikes or
other labor disputes at our locations which are unionized or are subject to
national contracts which could affect our operations.

24

WE RELY HEAVILY UPON KEY DISTRIBUTORS, AND WE COULD LOSE SALES IF ANY OF
THEM STOP DOING BUSINESS WITH US.

In fiscal 2002, approximately 22% of our sales were made through our top
five independent distributors. Mergers and consolidation of our distributors
have temporarily slowed sales of our products in the past and may do so in the
future. We believe that the loss of either Henry Schein, Inc. or Patterson
Dental Co., the only distributors who account for more than 5% of our sales,
could have a material adverse effect on our results of operations or financial
condition until we find alternative means to distribute our products.

WE ARE SUBJECT TO PRODUCT LIABILITY LITIGATION AND RELATED RISKS WHICH
COULD ADVERSELY AFFECT OUR BUSINESS.

Because many of our products are designed for use in and around a patient's
mouth, and because many of these products contain chemicals, metals, and other
materials, we are subject to claims and litigation brought by patients or dental
professionals alleging harm caused by the use of or exposure to our products. We
may need to devote substantial amounts of time and attention to defending
ourselves and may also be required to pay large amounts in settlement or upon
judgment. We may also be required to or may voluntarily recall products, which
would require substantial effort and cost. Litigation or a product recall could
divert significant amounts of our management's time from other important
matters. Our business could also be adversely affected by public perceptions
about the safety of our products, whether or not any such concerns are
justified.

OUR BUSINESS IS SUBJECT TO QUARTERLY VARIATIONS IN OPERATING RESULTS DUE TO
FACTORS OUTSIDE OF OUR CONTROL.

Our business is subject to quarterly variations in operating results caused
by a number of factors, including business and industry conditions, the timing
of acquisitions, distribution chain issues, and other factors beyond our
control. All these factors make it difficult to predict operating results for
any particular period. We may be subject to risks arising from other business
and investment considerations that may be disclosed from time to time in our
Securities and Exchange Commission filings or in other publicly written
documents.

CHANGES IN INTERNATIONAL TRADE LAWS AND IN THE BUSINESS, POLITICAL AND
REGULATORY ENVIRONMENT ABROAD COULD MATERIALLY ADVERSELY AFFECT OUR BUSINESS.

Our foreign operations include manufacturing facilities in Canada,
Switzerland, Italy and Mexico. Accordingly, an event that has a material adverse
impact on our foreign operations may materially adversely affect our operations
as a whole. The business, regulatory and political environments in countries
where we have operations differ from those in the United States and our foreign
operations are exposed to a number of inherent risks, including, but not limited
to:

o changes in international trade laws, such as the North American Free
Trade Agreement, or NAFTA, affecting our activities in Mexico and
Canada;

o changes in local labor laws and regulations affecting our ability to
hire and retain local employees;

o currency exchange restrictions and fluctuations in the value of foreign
currency;

o potentially adverse tax consequences;

o longer payment cycles;

o greater difficulties in collecting accounts receivable;

o political conditions in countries where we have operations;

o unexpected changes in the regulatory environment; and

o changes in general economic conditions in countries, such as Italy and
Mexico, that have historically been less stable than the United States.

If any of the events described were to occur, it could have a material
adverse effect on our business, financial condition and results of operations.

25

AS WE INCUR MORE INDEBTEDNESS AND GREATER INTEREST EXPENSE, WE MAY NOT BE
ABLE TO MAINTAIN OUR LEVEL OF INVESTMENT IN RESEARCH AND DEVELOPMENT.

The indenture relating to our Senior Subordinated Notes and our Credit
Facility permit us to incur significant amounts of additional debt. If we incur
additional debt, our interest expense will rise. We may find we do not have
enough available cash to pay for the increased interest expense and other
budgeted expenses. We may need to reduce our discretionary expenses, including
research and development, which could reduce or delay the introduction of new
products. We may not be able to maintain our level of investment in research and
development as we incur more indebtedness and greater interest expense.

WE OPERATE IN A HIGHLY COMPETITIVE INDUSTRY AND WE CANNOT BE CERTAIN THAT WE
WILL BE ABLE TO COMPETE EFFECTIVELY.

Numerous competitors participate in our business segments, some of which
have substantially greater financial and other resources than we do. Our
principal competitors in the Professional Dental Business segment include
Dentsply International Inc., 3M Corporation and its affiliate ESPE GmbH & Co.,
Ivoclar Vivadent Group, Johnson & Johnson, Steris Corporation, and Ecolab, Inc.;
and in the Orthodontics business segment, our principal competitors include
Unitek, a subsidiary of 3M Corporation, GAC Orthodontics, a subsidiary of
Dentsply, and American Orthodontics. We may face increased competition from
these or other companies in the future and we may not be able to achieve or
maintain adequate market share or margins, or compete effectively, in any of our
markets. Any of the foregoing factors could adversely affect our revenues and
operating profits and hinder our future expansion.

CERTAIN OF OUR PRODUCTS AND MANUFACTURING FACILITIES ARE SUBJECT TO
REGULATION, AND OUR FAILURE TO OBTAIN OR MAINTAIN THE REQUIRED REGULATORY
APPROVALS FOR THESE PRODUCTS COULD HINDER OR PREVENT THEIR SALE AND INCREASE OUR
COSTS OF REGULATORY COMPLIANCE.

Our ability to continue manufacturing and selling those of our products that
are subject to regulation by the United States Food and Drug Administration,
state laws or other domestic or foreign governments or agencies is subject to a
number of risks, including the promulgation of stricter laws or regulations,
reclassification of our products into categories subject to more stringent
requirements, or the withdrawal of the approval needed to sell one or more of
our products. The costs of complying with these regulations and the delays in
receiving required regulatory approvals or the enactment of new adverse
regulations or regulatory requirements may force us to cut back our operations,
recall products, increase our costs of regulatory compliance, prevent us from
selling a product or hinder our growth.

WE MAY BE REQUIRED TO SATISFY CERTAIN INDEMNIFICATION OBLIGATIONS TO
APOGENT, OR MAY NOT BE ABLE TO COLLECT ON INDEMNIFICATION RIGHTS FROM APOGENT.

Pursuant to the terms of the agreements executed in connection with our
spin-off from Apogent, we and our U.S. subsidiaries, in general, indemnify
Apogent and its subsidiaries and affiliates against liabilities, litigation and
claims actually or allegedly arising out of the dental business, including
discontinued operations relating to our business. Similarly, Apogent and its
U.S. subsidiaries indemnify us and our subsidiaries and affiliates against
liabilities, litigation and claims actually or allegedly arising out of
Apogent's business, including discontinued operations related to the laboratory
business, and other operations and assets not transferred to us. These
indemnification obligations could be significant. The availability of these
indemnities will depend upon the future financial strength of each of the
companies. We cannot determine whether we will have substantial indemnification
obligations to Apogent and its affiliates in the future. We also cannot assure
you that, if Apogent has substantial indemnification obligations to us and our
affiliates, Apogent will have the ability to satisfy those obligations.

WE COULD BE ADVERSELY AFFECTED IF THE SPIN-OFF IS NOT TAX FREE; WE HAVE
AGREED TO INDEMNIFY APOGENT IF WE EXPERIENCE A CHANGE IN CONTROL THAT CAUSES THE
SPIN-OFF TO BE TAXABLE.

In connection with the spin-off, Apogent received rulings from the Internal
Revenue Service that, for federal income tax purposes, the transactions
undertaken in connection with the spin-off, and the spin-off itself, would be
tax free to Apogent and its shareholders. These rulings are subject to the
validity of factual representations made to the IRS and assumptions and
conditions set out in the ruling request. In order to assure that the
representations made in connection with the ruling request are true, we have
agreed with Apogent to certain restrictions on future actions for a period of
time following the spin-off. In particular, we have agreed to continue the
active conduct of our historic business for a minimum of two years, and we have
agreed not to issue stock, merge with another corporation, or dispose of our
assets in a manner that would cause the spin-off to be treated as part of a plan
pursuant to which one or more persons acquire a 50% or greater interest in our
stock. We have agreed to indemnify Apogent if the spin-off is treated as having
been taxable by reason of any breach of these agreements. Our indemnification of
Apogent for these liabilities would have a material adverse effect on our
financial condition and results of operations.

26

Except as may be required by applicable securities laws or regulations, we
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

FOREIGN EXCHANGE CURRENCY RISK MANAGEMENT

We operate internationally; therefore, our earnings, cash flows, and
financial position are exposed to foreign currency risk from foreign currency
denominated receivables and payables, forecasted sales transactions, as well as
net investments in certain foreign operations. These items are denominated in
foreign currencies, including but not limited to the euro, Japanese yen, Swiss
franc, Mexican peso, Canadian dollar, and the Australian dollar.

We believe it is prudent to minimize the variability caused by foreign
currency risk. We attempt to minimize foreign currency risk by using derivative
instruments when prudent. We do not use derivative instruments for purposes
other than hedging.

Although we have a U.S. dollar functional currency, a substantial portion of
our sales, income, and cash flow are derived from foreign currencies. Our
foreign currency exposure exists primarily in the euro, Japanese yen, Canadian
dollar, Swiss franc, Mexican peso and Australian dollar versus the U.S. dollar.

For fiscal year 2003, our projected total foreign currency exposure is
approximately 52.7 million euros, 897.1 million Japanese yen, 13.5 million
Canadian dollars, 15.4 million Australian dollars, and 3.1 million Swiss francs.
We have put in place a strategy to manage our euro and Japanese yen cash flow
exposure through the use of zero cost collar contracts. There were no such
contracts in place for the Canadian dollar, Australian dollar, and Swiss franc
at December 31, 2002.

In July 2002, we entered into a zero cost collar contract to hedge
intercompany transactions with a notional amount of 24.0 million euros for
fiscal year 2003. In November 2002, we entered into an additional zero cost
collar contract to hedge intercompany transactions with a notional amount of
16.5 million euros for fiscal year 2003. Also, in June 2002, we entered into a
zero cost collar contract to hedge a notional amount of 720.0 million Japanese
yen for fiscal year 2003.

At December 31, 2002, approximately $0.7 million of loss (net of income tax)
representing the fair value of the zero cost collars, is included in accumulated
other comprehensive income (loss), related to the foreign currency zero cost
collar transactions. In addition, none of the foreign currency cash flow hedges
has been discontinued.

Zero cost collar contracts in place as of December 31, 2002 are as follows
(in thousands, except rates):

As of December 31, 2002, the maximum length of time over which we are
hedging our exposure to the variability in future cash flows associated with
foreign currency forecasted transaction is nine months for the Japanese yen and
nine months for the euro.

In September 2001, we entered into a cross currency debt swap transaction to
hedge our net investment in Hawe Neos. The agreement had an effective date of
October 16, 2001, and was a contract to exchange a U.S. dollar principal amount
of $45.0 million in exchange for a Swiss franc principal amount of 71.73 million
at the termination date of October 16, 2006. On June 6, 2002, we terminated this
cross currency debt swap transaction to satisfy requirements under our Credit
Facility. As of June 30, 2002, we entered into four cross currency debt swap
transactions to hedge our net investment in Hawe Neos and one cross currency
debt swap to hedge our net investment in SDS Japan. The agreements to hedge our
net investment in Hawe Neos have a total aggregate notional amount of $45.0
million and the agreement relating to SDS Japan has a notional amount of $4.0
million. The mechanics of the new agreements are similar to the original cross
currency debt swap terminated on June 6, 2002. However, the fixed interest rate
to be paid to us in the U.S. dollar leg of the agreements is the rate equal to
the Senior Subordinated Notes rate of 8 1/8% while the fixed interest rate to be
paid by us in the Swiss franc leg of the agreements ranges from 6.39% to 6.45%
and the Japanese yen leg of the agreements is 3.65%, with the interest payments
due semi-annually.

27

Following are the details of the new cross currency debt swaps (amounts in
millions, except rates):

At December 31, 2002, the fair value of the cross currency debt swap
transaction gain included in translation adjustments was approximately $2.5
million (net of income tax).

As a result of terminating the cross currency debt swap transaction to hedge
our net investment in Hawe Neos, we recognized a loss to the translation
adjustment, a component of other comprehensive income (loss) in the amount of
approximately $0.9 million (net of income tax). This amount will remain in
translation adjustment, a component of other comprehensive income (loss) until
sale or upon complete or substantially complete liquidation of our net
investment in Hawe Neos.

INTEREST RATE EXPOSURE -- INTEREST RATE RISK MANAGEMENT

We use our Credit Facility and Senior Subordinated Notes to finance our
operations. The Credit Facility exposes us to variability in interest payments
due to changes in interest rates. If interest rates increase, interest expense
increases. Conversely, if interest rates decrease, interest expense also
decreases. Under our prior credit facility, we were required to have interest
rate protection for a specified portion of the outstanding balances for a
specified period of time. Although we paid off and terminated that prior credit
facility, we retained certain of the interest rate swap agreements we had
entered into to manage fluctuations in cash flows resulting from interest rate
risk. These interest rate swaps change a portion of our variable-rate cash flow
exposure to fixed-rate cash flows.

We continue to assess our exposure to interest rate risk on an ongoing
basis.

The table below provides information about our debt obligations that are
sensitive to changes in interest rates as of December 31, 2002. For these debt
obligations, the table presents principal cash flows and related weighted
average interest rates by expected maturity dates. Weighted average variable
rates are based on implied forward 3-month LIBOR rates in the yield curve at the
reporting date. The information is presented in U.S. dollar equivalents, which
is our reporting currency.

For the quarter ended December 31, 2002, the total net cost of converting
from floating rate (3-month LIBOR) to fixed rate for a portion of the interest
payments under our long-term debt obligations was approximately $0.1 million. At
December 31, 2002, approximately $2.3 million loss (net of income tax) is
included in accumulated other comprehensive income (loss). Below is a table
listing the interest expense exposure detail and the fair value of the interest
rate swap agreements as of December 31, 2002 (dollars in thousands):

The fair value of interest rate swap agreements designated as hedging
instruments against the variability of cash flows associated with floating-rate,
long-term debt obligations are reported in accumulated other comprehensive
income (loss). These amounts subsequently are reclassified into interest expense
as a yield adjustment in the same period in which the related interest on the
floating-rate debt obligations affects earnings.

On June 6, 2002 we entered into a $350.0 million syndicated credit facility
for which Credit Suisse First Boston is the administrative agent. This Credit
Facility provides for a five-year $120.0 million Revolver, a seven-year $200.0
million Term Loan B and a five-year $30.0 million Euro Tranche revolving credit
facility. In addition to the Credit Facility, we completed the sale of $150.0
million of Senior Subordinated Notes at 8 1/8% interest, due 2012, in a private
offering. We used the proceeds of the Term Loan B,

28

together with proceeds from the issuance of the Senior Subordinated Notes, to
repay all of the $332.9 million of borrowings outstanding as of June 6, 2002
under our previous credit facility.

Approximately $70.0 million of our then-existing interest rate swaps could
not be re-assigned to our Credit Facility entered into on June 6, 2002 and thus
were terminated. Accordingly, we recorded a loss on derivative instruments of
approximately $3.8 million (or approximately $2.3 million, net of tax) in other
income (expense), which represents the fair value of the swaps at the
termination date. Additionally, we had to de-designate the remaining interest
rate swaps as a result of the specificity of our hedge documentation relating to
the hedged item. Accordingly, a non-cash loss on derivative instruments of
approximately $3.2 million (or approximately $2.0 million, net of tax),
representing the fair value of the remaining swaps at the date of the
refinancing, was reclassified from accumulated other comprehensive income (loss)
and recorded in other income (expense) to recognize the loss. However, these
swaps were continued and were simultaneously re-assigned to the Credit Facility.
The change in the fair value of these re-assigned swaps from the refinancing
date to December 31, 2002 has been recorded in accumulated other comprehensive
income (loss).

The re-assigned interest rate swap agreements are expected to be highly
effective as we expect the hedging relationship to meet the relevant hedge
accounting criteria of SFAS No. 133. The re-assigned interest rate swap
agreements showed no recognizable ineffectiveness during the quarter ended
December 31, 2002.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We have disclosure controls and procedures in place, which are designed to
ensure that material information related to SDS, including our consolidated
subsidiaries, is made known to our management, including our Chief Executive
Officer ("CEO") and Chief Financial Officer ("CFO"). We review our disclosure
controls and procedures regularly and when necessary and make changes to ensure
they are effective.

Within the 90 day period prior the date of this report, an evaluation was
carried out under the supervision and with the participation of our management,
including the CEO and the CFO, of the effectiveness of our disclosure controls
and procedures. Based upon that evaluation, the CEO and CFO have concluded that
SDS's disclosure controls and procedures are effective in causing material
information to be collected and evaluated by the management of the Company on a
timely basis and to ensure that the quality and timeliness of our public
disclosures complies with our SEC disclosure obligations.

CHANGES IN INTERNAL CONTROLS

There were no significant changes in our internal controls or in other
factors that could significantly affect those controls after the date of our
most recent evaluation.

29

PART II - OTHER INFORMATION

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company, a Delaware corporation, held its Annual Meeting of Stockholders
on February 7, 2003. A quorum was present at the Annual Meeting, with 33,499,096
shares out of a total of 37,989,650 shares entitled to cast votes represented in
person or by proxy at the meeting.

PROPOSAL 1: To elect two directors to serve as Class III Directors until the
2006 Annual Meeting of Stockholders and until their respective
successors are duly elected and qualified.

The stockholders voted to elect Donald N. Ecker and Robert W. Klemme to
serve as Class III directors until the 2006 Annual Meeting of Stockholders and
until their respective successors are duly elected and qualified. The results of
the vote are as follows:

The terms of office as directors of Floyd W. Pickrell, Jr., William E. B.
Siart, James R. Parks, Kenneth F. Yontz and Dennis B. Brown continued after the
meeting.

PROPOSAL 2: To consider and vote upon a proposal to approve the Company's
Employee Stock Purchase Plan.

The stockholders voted to approve the Company's Employee Stock Purchase
Plan. The results of the vote are as follows:

For ................................................... 32,953,396
Against ............................................... 528,184
Abstentions ........................................... 17,516
Broker Non-Votes ...................................... 0

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) EXHIBITS:

See the Exhibit Index following the Signature page in this report, which is
incorporated herein by reference.

(b) REPORTS ON FORM 8-K:

No reports on Form 8-K were filed during the quarter for which this report
is filed.

30

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

SYBRON DENTAL SPECIALTIES, INC
(Registrant)

Date: February 14, 2003 /s/ GREGORY D. WALLER
--------------------------------------------
Gregory D. Waller
Vice President - Finance,
Chief Financial Officer & Treasurer*

* executing as both the principal
financial officer and a duly
authorized officer of the Company.

31

CERTIFICATIONS

I, Floyd W. Pickrell, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sybron Dental
Specialties, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
we have:

(a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;

(b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date
of this quarterly report (the "Evaluation Date"); and

(c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the
audit committee of registrant's board of directors (or persons
performing the equivalent function):

(a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and

(b) any fraud, whether or not material, that involves management of
other employees who have a significant role in the registrant's
internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether there or not were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies
and material weaknesses.

/s/ FLOYD W. PICKRELL, JR.
-----------------------------------
Chief Executive Officer

Dated: February 14, 2003

32

I, Gregory D. Waller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sybron Dental
Specialties, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and
we have:

(a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;

(b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date
of this quarterly report (the "Evaluation Date"); and

(c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based
on our most recent evaluation, to the registrant's auditors and the
audit committee of registrant's board of directors (or persons
performing the equivalent function):

(a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and

(b) any fraud, whether or not material, that involves management of
other employees who have a significant role in the registrant's
internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant deficiencies
and material weaknesses.

/s/ GREGORY D. WALLER
-----------------------------------
Chief Financial Officer

Dated: February 14, 2003

33

SYBRON DENTAL SPECIALTIES, INC.
(THE "REGISTRANT")
(COMMISSION FILE NO. 1-16057)
EXHIBIT INDEX
TO
QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2002